The trajectory of cortical GABA across the lifespan, an individual participant data meta-analysis of edited MRS studies

  1. Eric C Porges  Is a corresponding author
  2. Greg Jensen
  3. Brent Foster
  4. Richard AE Edden PhD
  5. Nicolaas AJ Puts
  1. University of Florida, United States
  2. Columbia University, United States
  3. Johns Hopkins University School of Medicine, United States
  4. King's College London, United Kingdom

Abstract

GABA is the principal inhibitory neurotransmitter in the human brain and can be measured with Magnetic Resonance Spectroscopy (MRS). Conflicting accounts report decreases and increases in cortical GABA levels across the lifespan. This incompatibility may be an artifact of the size and age-range of the samples utilized in these studies. No single study to date has included the entire lifespan. In this study, 8 suitable datasets were integrated to generate a model of the trajectory of frontal GABA estimates (as reported through edited MRS; both expressed as ratios and in institutional units). across the lifespan. Data were fit using both a log-normal curve and a nonparametric spline as regression models using a multi-level Bayesian model utilizing the Stan language. Integrated data show the lifespan trajectory of frontal GABA measures involves an early period of increase, followed by a period of stability during early adulthood, with a gradual decrease during adulthood and aging that is described well by both spline and log-normal models. The information gained will provide a general framework to inform expectations of future studies based on the age of the population being studied.

Data availability

All data and code used in this manuscript can be found here https://osf.io/rmhwc/

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Eric C Porges

    Clinical and Health Psychology, University of Florida, Gainesville, United States
    For correspondence
    eporges@phhp.ufl.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3885-5859
  2. Greg Jensen

    Columbia University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Brent Foster

    Clinical and Health Psychology, University of Florida, Gainesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Richard AE Edden PhD

    Johns Hopkins University School of Medicine, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Nicolaas AJ Puts

    King's College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.

Funding

National Institutes of Health (KO1AA025306)

  • Eric C Porges

Evelyn F. McKnight Brain Research Foundation

  • Eric C Porges

Center for Cognitive Aging and Memory at the University of Florida

  • Eric C Porges

National Institutes of Health (R00MH107719)

  • Nicolaas AJ Puts

National Institutes of Health (R01EB016089)

  • Richard AE Edden PhD

National Institutes of Health (R01MH106564)

  • Richard AE Edden PhD

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Chris I Baker, National Institute of Mental Health, National Institutes of Health, United States

Version history

  1. Received: August 28, 2020
  2. Accepted: May 30, 2021
  3. Accepted Manuscript published: June 1, 2021 (version 1)
  4. Version of Record published: June 24, 2021 (version 2)

Copyright

© 2021, Porges et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,555
    Page views
  • 276
    Downloads
  • 36
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Eric C Porges
  2. Greg Jensen
  3. Brent Foster
  4. Richard AE Edden PhD
  5. Nicolaas AJ Puts
(2021)
The trajectory of cortical GABA across the lifespan, an individual participant data meta-analysis of edited MRS studies
eLife 10:e62575.
https://doi.org/10.7554/eLife.62575

Share this article

https://doi.org/10.7554/eLife.62575

Further reading

    1. Neuroscience
    Kiwamu Kudo, Kamalini G Ranasinghe ... Srikantan S Nagarajan
    Research Article

    Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β and misfolded tau proteins causing synaptic dysfunction, and progressive neurodegeneration and cognitive decline. Altered neural oscillations have been consistently demonstrated in AD. However, the trajectories of abnormal neural oscillations in AD progression and their relationship to neurodegeneration and cognitive decline are unknown. Here, we deployed robust event-based sequencing models (EBMs) to investigate the trajectories of long-range and local neural synchrony across AD stages, estimated from resting-state magnetoencephalography. The increases in neural synchrony in the delta-theta band and the decreases in the alpha and beta bands showed progressive changes throughout the stages of the EBM. Decreases in alpha and beta band synchrony preceded both neurodegeneration and cognitive decline, indicating that frequency-specific neuronal synchrony abnormalities are early manifestations of AD pathophysiology. The long-range synchrony effects were greater than the local synchrony, indicating a greater sensitivity of connectivity metrics involving multiple regions of the brain. These results demonstrate the evolution of functional neuronal deficits along the sequence of AD progression.

    1. Medicine
    2. Neuroscience
    Luisa Fassi, Shachar Hochman ... Roi Cohen Kadosh
    Research Article

    In recent years, there has been debate about the effectiveness of treatments from different fields, such as neurostimulation, neurofeedback, brain training, and pharmacotherapy. This debate has been fuelled by contradictory and nuanced experimental findings. Notably, the effectiveness of a given treatment is commonly evaluated by comparing the effect of the active treatment versus the placebo on human health and/or behaviour. However, this approach neglects the individual’s subjective experience of the type of treatment she or he received in establishing treatment efficacy. Here, we show that individual differences in subjective treatment - the thought of receiving the active or placebo condition during an experiment - can explain variability in outcomes better than the actual treatment. We analysed four independent datasets (N = 387 participants), including clinical patients and healthy adults from different age groups who were exposed to different neurostimulation treatments (transcranial magnetic stimulation: Studies 1 and 2; transcranial direct current stimulation: Studies 3 and 4). Our findings show that the inclusion of subjective treatment can provide a better model fit either alone or in interaction with objective treatment (defined as the condition to which participants are assigned in the experiment). These results demonstrate the significant contribution of subjective experience in explaining the variability of clinical, cognitive, and behavioural outcomes. We advocate for existing and future studies in clinical and non-clinical research to start accounting for participants’ subjective beliefs and their interplay with objective treatment when assessing the efficacy of treatments. This approach will be crucial in providing a more accurate estimation of the treatment effect and its source, allowing the development of effective and reproducible interventions.